207 related articles for article (PubMed ID: 9751500)
1. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors.
Liu Y; Takeshita A; Misiti S; Chin WW; Yen PM
Endocrinology; 1998 Oct; 139(10):4197-204. PubMed ID: 9751500
[TBL] [Abstract][Full Text] [Related]
2. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
Tagami T; Jameson JL
Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
[TBL] [Abstract][Full Text] [Related]
3. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.
Safer JD; Cohen RN; Hollenberg AN; Wondisford FE
J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773
[TBL] [Abstract][Full Text] [Related]
4. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators.
Tagami T; Gu WX; Peairs PT; West BL; Jameson JL
Mol Endocrinol; 1998 Dec; 12(12):1888-902. PubMed ID: 9849963
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.
Jeyakumar M; Tanen MR; Bagchi MK
Mol Endocrinol; 1997 Jun; 11(6):755-67. PubMed ID: 9171239
[TBL] [Abstract][Full Text] [Related]
6. Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR).
Loinder K; Söderström M
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):191-6. PubMed ID: 15336696
[TBL] [Abstract][Full Text] [Related]
7. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.
Shibata H; Spencer TE; Oñate SA; Jenster G; Tsai SY; Tsai MJ; O'Malley BW
Recent Prog Horm Res; 1997; 52():141-64; discussion 164-5. PubMed ID: 9238851
[TBL] [Abstract][Full Text] [Related]
8. Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators.
Lin KH; Wu YH; Chen SL
Endocrinology; 2001 Feb; 142(2):653-62. PubMed ID: 11159836
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of DNA binding affinity and dimerization properties of wild-type and mutant thyroid hormone receptor beta1.
Takeda T; Nagasawa T; Miyamoto T; Minemura K; Hashizume K; Degroot LJ
Thyroid; 2000 Jan; 10(1):11-8. PubMed ID: 10691308
[TBL] [Abstract][Full Text] [Related]
10. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
[TBL] [Abstract][Full Text] [Related]
11. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
Ng L; Forrest D; Haugen BR; Wood WM; Curran T
Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
[TBL] [Abstract][Full Text] [Related]
12. Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation.
Li X; Kimbrel EA; Kenan DJ; McDonnell DP
Mol Endocrinol; 2002 Jul; 16(7):1482-91. PubMed ID: 12089344
[TBL] [Abstract][Full Text] [Related]
13. A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone.
Wu SY; Cohen RN; Simsek E; Senses DA; Yar NE; Grasberger H; Noel J; Refetoff S; Weiss RE
J Clin Endocrinol Metab; 2006 May; 91(5):1887-95. PubMed ID: 16464943
[TBL] [Abstract][Full Text] [Related]
14. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
Piedrafita FJ; Ortiz MA; Pfahl M
Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
[TBL] [Abstract][Full Text] [Related]
15. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
[TBL] [Abstract][Full Text] [Related]
16. Understanding the molecular mechanism of dominant negative action of mutant thyroid hormone beta 1-receptors: the important role of the wild-type/mutant receptor heterodimer.
Zhu XG; Yu CL; McPhie P; Wong R; Cheng SY
Endocrinology; 1996 Feb; 137(2):712-21. PubMed ID: 8593822
[TBL] [Abstract][Full Text] [Related]
17. TR surfaces and conformations required to bind nuclear receptor corepressor.
Marimuthu A; Feng W; Tagami T; Nguyen H; Jameson JL; Fletterick RJ; Baxter JD; West BL
Mol Endocrinol; 2002 Feb; 16(2):271-86. PubMed ID: 11818500
[TBL] [Abstract][Full Text] [Related]
18. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor.
Jeyakumar M; Webb P; Baxter JD; Scanlan TS; Katzenellenbogen JA
Biochemistry; 2008 Jul; 47(28):7465-76. PubMed ID: 18558711
[TBL] [Abstract][Full Text] [Related]
19. Regulation of nuclear coactivator and corepressor expression in mouse cerebellum by thyroid hormone.
Ramos HE; Weiss RE
Thyroid; 2006 Mar; 16(3):211-6. PubMed ID: 16571082
[TBL] [Abstract][Full Text] [Related]
20. Requirement of corepressor binding of thyroid hormone receptor mutants for dominant negative inhibition.
Nagaya T; Fujieda M; Seo H
Biochem Biophys Res Commun; 1998 Jun; 247(3):620-3. PubMed ID: 9647743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
